Krka Banned from Selling Zyllt in Serbia again

Novo Mesto, 23 November - Slovenian drug maker Krka has again been banned from importing and selling its anticoagulant Zyllt in Serbia. The Commercial Court of Novi Sad ruled that the sale of Zyllt in Serbia constitutes an infringement of the plaintiff's patent that protects the active ingredient clopidogrel in the hydrogen sulphate salt form, which is also an ingredient of Zyllt.